| Ytd | -37.70% | |
| 1y | -26.69% |
| Open | 7.62 | Prev Close | 7.62 | Low | 7.58 | High | 8.08 | Mkt Cap | 624.84M |
| Vol | 479.24K | Avg Vol | 462.99K | EPS | -1.92 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 4.43 | Inst. Own | 52.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.18 | 200-d Avg | 10.45 | 1yr Est | 24.20 |
BBOT News
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent dec
Top Wall Street analysts changed outlook on top names. For full rating changes, check analyst rating
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceu
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally adv
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the O
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Bu
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analy
Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Bu
Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform
Morgan Stanley analyst Sean Laaman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform